Steen Meier Knudsen

Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark.

Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark.

Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark.

Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark.